Lilly putting $400M into U.S. diabetes production, adding 100 jobs

Eli Lilly's capacity for making insulin and other diabetes drugs is being expanded at its headquarter's site in Indianapolis, Indiana. ( Eli Lilly)

Eli Lilly faced critics of rising insulin prices this year by introducing a generic version of its popular Humalog priced at half the cost. Now the drugmaker is investing $400 million in its Indianapolis production site so it can make more diabetes treatments and prepare for pipeline products.

While the investment will add robots and other new technology, it will result in 100 new jobs. 

"These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," Myles O'Neill, president of Lilly’s manufacturing operations said in a statement. "All of these projects support Lilly's investment in next-generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics."


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Among other enhancements, a spokeswoman said in an email that upgrades to the device and packaging assembly operations will include a high-tech warehouse using the latest technologies in warehousing, automated guided vehicles and robotics.

RELATED: Lilly's $7M tax abatement in Indianapolis draws bipartisan pushback: reports

The company credited the 2017 federal tax cut legislation for helping support the expansion. 

Lilly, along with Sanofi and Novo Nordisk, were named this year during Senate hearings into rising insulin prices. Lilly’s Humalog’s list price was called out as a prime example of routine price hikes that limit patient access. 

RELATED: Lilly to insulin pricing critics: Check out our 50%-off Humalog copy instead

Drugmakers have responded by pushing the blame for higher prices on pharmacy benefit managers. Lilly has pointed out that while Humalog’s list has fattened by 52% over five years, its net price has shrunk 8%.

But Lilly acted to quell criticism nonetheless. In May, Lilly released its Lispro injection, a Humalog copy that at $265.20 for a five-pack of pens, is 50% cheaper than the branded drug. 

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.